Development and application of a digital platform for standardized quality control of thyroid cancer diagnosis and treatment_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XU Jiajie ^1,2,3,4 , CHEN Yiwei ⁵ , CHEN Keyu ⁵ , HUANG Xingyu ⁵ , TAN Zhuo ^1,2,3,4 , ZHENG Chuanming ^1,2,3,4 , XIN Ying ^1,2,3,4 , TAN Mingming ⁶ , GUO Haiwei ^1,2,3,4 , GUO Yawen ^1,2,3,4 ,  YANG Wenjing ⁷ ,  GE Minghua ^1,2,3,4

1. Department of Head and Neck Surgery, Otolaryngology & Head and Neck Center, Cancer Center, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital of Hangzhou Medical College), Hangzhou 310014, P. R. China;
2. Thyroid Cancer Expert Committee of National Cancer Quality Control Center, National Cancer Center, Beijing 100000, P. R. China;
3. Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou 310014, P. R. China;
4. Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou 310014, P. R. China;
5. Second Clinical Medical College, Zhejiang University of Chinese Medicine, Hangzhou 310014, P. R. China;
6. Department of Quality Management, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital of Hangzhou Medical College), Hangzhou 310014, P. R. China;
7. National Cancer Center, National Cancer Clinical Medical Research Center; Quality Control Office of Cancer Diagnosis and Treatment, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100000, P. R. China;

Corresponding?author：

YANG Wenjing, Email: wenjing86824@126.com; GE Minghua, Email: geminghua@hmc.edu.cn

Keywords：

thyroid cancer; quality control; digital platform; clinical diagnosis and treatment

DOI：

10.7507/1007-9424.202410063

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective Explore the impact of a digital-intelligence-based quality control platform for thyroid cancer on the effectiveness of clinical diagnosis and treatment quality management. Methods The digital-intelligence-based quality control platform for thyroid cancer at Zhejiang Provincial People’s Hospital was launched at the end of July 2022. In its initial phase, six quality control indicators related to the standardized diagnosis and treatment of thyroid cancer were deployed. This study analyzed the changes in these six quality control indicators between January 2022 and November 2023, comparing data before and after the platform’s implementation. Results Compared with the period from January to July 2022 (prior to the platform’s launch), the rates of preoperative cytopathological examination (t=–8.490, P<0.001) and postoperative pTNM staging for thyroid cancer patients (t=–3.027, P=0.013) increased from July to November 2023 (one year post-launch). However, the proportion of minimally invasive surgeries among thyroid cancer patients (t=4.085, P=0.002) decreased. The linear regression model results indicated that, following the platform’s launch, there was a gradual increase over time in both the preoperative cytopathological examination rate for thyroid cancer (P=0.001) and the postoperative pTNM staging rate (P=0.049). Conclusion Preliminary results of this study suggest that the thyroid cancer digital-intelligence-based quality control platform developed by our team can effectively enhance the standardized quality control of clinical diagnosis and treatment for thyroid cancer.

Citation： XU Jiajie, CHEN Yiwei, CHEN Keyu, HUANG Xingyu, TAN Zhuo, ZHENG Chuanming, XIN Ying, TAN Mingming, GUO Haiwei, GUO Yawen, YANG Wenjing, GE Minghua. Development and application of a digital platform for standardized quality control of thyroid cancer diagnosis and treatment. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(11): 1358-1363. doi: 10.7507/1007-9424.202410063 Copy

1.	文靜, 殷成宇, 廖國偉, 等. 應用GM(1, 1)灰色模型預測全國甲狀腺癌發病趨勢. 現代腫瘤醫學, 2022, 30(5): 899-902.
2.	Yan KL, Li S, Tseng CH, et al. Rising incidence and incidence-based mortality of thyroid cancer in california, 2000-2017. J Clin Endocrinol Metab, 2020, 105(6): dgaa121. doi: 10.1210/clinem/dgaa121.
3.	何林燁, 王藝超, 李志輝. 2022年中國甲狀腺癌流行情況分析: 基于《中國腫瘤登記年報》2005–2018年數據. 中國普外基礎與臨床雜志, 2024, 31(7): 790-795. doi: 10.3390/healthcare10091621.
4.	Chen W, Zheng R, Zuo T, et al. National cancer incidence and mortality in China, 2012. Chin J Cancer Res, 2016, 28(1): 1-11.
5.	Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol, 2021, 9(4): 225-234.
6.	Horgan D, Führer-Sakel D, Soares P, et al. Tackling thyroid cancer in europe-the challenges and opportunities. Healthcare (Basel), 2022, 10(9): 1621. doi: 10.3390/healthcare10091621.
7.	楊曉勇, 于洋, 李大鵬, 等. 部分類型甲狀腺癌患者診治現狀與思考. 中華耳鼻咽喉頭頸外科雜志, 2017, 52(4): 305-308.
8.	國家癌癥中心, 國家腫瘤質控中心甲狀腺癌質控專家委員會. 中國甲狀腺癌規范診療質量控制指標(2022版). 中華腫瘤雜志, 2022, 44(9): 902-907.
9.	李剛, 陶紅兵, 唐錦輝, 等. 依托六大平臺實施醫療質量與安全精準化監管. 中國醫院管理, 2015, 35(1): 19-21.
10.	李娟, 李剛, 劉東, 等. 實施藥事精準化監管切實保障醫療質量與安全. 中國醫院管理, 2015, 35(1): 23-25.
11.	中國抗癌協會甲狀腺癌專業委員會. 中國抗癌協會甲狀腺癌整合診治指南 (2022精簡版). 中國腫瘤臨床, 2023, 50(7): 325-330.
12.	Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26(1): 1-133.
13.	Lango M, Flieder D, Arrangoiz R, et al. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid, 2013, 23(9): 1099-1105.
14.	Falvo L, Catania A, D’Andrea V, et al. Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. Ann Surg, 2005, 241(4): 640-646.
15.	尹凌雪, 石增霞, 王茜. 甲狀腺癌根治術圍術期抗菌藥物應用臨床研究. 中華醫院感染學雜志, 2014, 24(7): 1649-1650, 1707.
16.	Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data system (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol, 2017, 14(5): 587-595.
17.	Zhou J, Yin L, Wei X, et al. 2020 Chinese guidelines for ultrasound malignancy risk stratification of thyroid nodules: the C-TIRADS. Endocrine, 2020, 70(2): 256-279.
18.	Wu J, Li Y, Zhang M. Clinical value of FNA puncture feeling in the diagnosis of non-diagnostic and indeterminate thyroid nodules. Front Endocrinol (Lausanne), 2022, 13: 1022438. doi: 10.3389/fendo.2022.1022438.
19.	Zhi J, Wu Y, Hu L, et al. Assessment of the prognostic value and N1b changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma. Int J Clin Oncol, 2020, 25(1): 59-66.

1. 文靜, 殷成宇, 廖國偉, 等. 應用GM(1, 1)灰色模型預測全國甲狀腺癌發病趨勢. 現代腫瘤醫學, 2022, 30(5): 899-902.
2. Yan KL, Li S, Tseng CH, et al. Rising incidence and incidence-based mortality of thyroid cancer in california, 2000-2017. J Clin Endocrinol Metab, 2020, 105(6): dgaa121. doi: 10.1210/clinem/dgaa121.
3. 何林燁, 王藝超, 李志輝. 2022年中國甲狀腺癌流行情況分析: 基于《中國腫瘤登記年報》2005–2018年數據. 中國普外基礎與臨床雜志, 2024, 31(7): 790-795. doi: 10.3390/healthcare10091621.
4. Chen W, Zheng R, Zuo T, et al. National cancer incidence and mortality in China, 2012. Chin J Cancer Res, 2016, 28(1): 1-11.
5. Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol, 2021, 9(4): 225-234.
6. Horgan D, Führer-Sakel D, Soares P, et al. Tackling thyroid cancer in europe-the challenges and opportunities. Healthcare (Basel), 2022, 10(9): 1621. doi: 10.3390/healthcare10091621.
7. 楊曉勇, 于洋, 李大鵬, 等. 部分類型甲狀腺癌患者診治現狀與思考. 中華耳鼻咽喉頭頸外科雜志, 2017, 52(4): 305-308.
8. 國家癌癥中心, 國家腫瘤質控中心甲狀腺癌質控專家委員會. 中國甲狀腺癌規范診療質量控制指標(2022版). 中華腫瘤雜志, 2022, 44(9): 902-907.
9. 李剛, 陶紅兵, 唐錦輝, 等. 依托六大平臺實施醫療質量與安全精準化監管. 中國醫院管理, 2015, 35(1): 19-21.
10. 李娟, 李剛, 劉東, 等. 實施藥事精準化監管切實保障醫療質量與安全. 中國醫院管理, 2015, 35(1): 23-25.
11. 中國抗癌協會甲狀腺癌專業委員會. 中國抗癌協會甲狀腺癌整合診治指南 (2022精簡版). 中國腫瘤臨床, 2023, 50(7): 325-330.
12. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2016, 26(1): 1-133.
13. Lango M, Flieder D, Arrangoiz R, et al. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid, 2013, 23(9): 1099-1105.
14. Falvo L, Catania A, D’Andrea V, et al. Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. Ann Surg, 2005, 241(4): 640-646.
15. 尹凌雪, 石增霞, 王茜. 甲狀腺癌根治術圍術期抗菌藥物應用臨床研究. 中華醫院感染學雜志, 2014, 24(7): 1649-1650, 1707.
16. Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data system (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol, 2017, 14(5): 587-595.
17. Zhou J, Yin L, Wei X, et al. 2020 Chinese guidelines for ultrasound malignancy risk stratification of thyroid nodules: the C-TIRADS. Endocrine, 2020, 70(2): 256-279.
18. Wu J, Li Y, Zhang M. Clinical value of FNA puncture feeling in the diagnosis of non-diagnostic and indeterminate thyroid nodules. Front Endocrinol (Lausanne), 2022, 13: 1022438. doi: 10.3389/fendo.2022.1022438.
19. Zhi J, Wu Y, Hu L, et al. Assessment of the prognostic value and N1b changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma. Int J Clin Oncol, 2020, 25(1): 59-66.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Development and application of a digital platform for standardized quality control of thyroid cancer diagnosis and treatment

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content